The beneficial role of Asian-based RecurIndex test in the prognostic prediction in Chinese male breast cancer patients

Shuo Zhang1,6, Beichen Liu2,6, Mengli Zhou3, Jintian Wang1, Jinzhao Liu1, Li Wang4, Chao Yang1, Yueping Liu5, Shuyao Niu5, Furong Du3, Xiaohua Du3, Ning Wang3, Jiyu Tang3, Chao Song3* & Yunjiang Liu1*

RecurIndex, a multigene profiling assay, can predict the risk of local recurrence and distant metastasis in female breast cancer (FBC), but its role in male breast cancer (MBC) remains unclear. In this study, the clinicopathological data of 43 consecutive MBC patients undergoing surgeries between 2009 and 2018 were retrospectively analysed. Their paraffin-embedded tissue sections were examined by RecurIndex test which comprised 2 models: recurrence index for local recurrence (RI-LR) and recurrence index for distant recurrence (RI-DR). Of 43 patients, there were 26 low-risk and 17 high-risk patients assessed by RI-LR, while 17 low-risk and 26 high-risk patients by RI-DR. For RI-LR, tumor N stage showed statistically significant (P < 0.001) between low- and high-risk patients; for RI-DR, differences were pronounced in tumor grade (P = 0.033), T stage (P = 0.043) and N stage (P = 0.003). In terms of clinical outcomes, the overall survival (OS) of low- and high-risk patients stratified by RI-LR showed no statistically significant differences (P = 0.460), while high-risk patients identified by RI-DR had a significantly worse distant recurrence-free survival (DRFS) (P = 0.035), progression-free survival (PFS) (P = 0.019) and OS (P = 0.044) than low-risk patients. Overall, RI-DR can effectively predict the DRFS, PFS and OS of MBC patients and identify those at low risk of recurrence, which may serve as a potential prognostic tool for MBC.

Male breast cancer (MBC) is a rare malignancy, approximately accounting for 1% of cancers in men and 1% of all breast cancers worldwide1-3. The incidence of MBC varies by ethnicities and geographical areas, with a high proportion of cases in Africa.4 According to the statistics, less than 0.2% of cancer-related deaths in men are ascribed to MBC1,5. In China, 0.4% newly diagnosed cases of MBC and 0.1% deaths were estimated in 20155. Because MBC occurs at a very low incidence, its epidemiology, tumour behaviour, treatment options and prognosis are still unclear. Although MBC is similar to female breast cancer (FBC) in many ways5, the tumour biology is different. In contrast to FBC, MBC is usually diagnosed at an older age, with more frequent lymph node metastases and higher rates of estrogen receptor (ER)-positive tumours5,8, and it is more likely to occur within the setting of BRCA2 mutations rather than BRCA1 mutations6. In addition, a low androgen state is also considered as a known risk factor for MBC10.

Currently, the treatment strategies for MBC are mainly based on the data extrapolated from the females. Relatively little is known about the vital clinical and genomic differences between males and females. Previous studies showed that MBC patients had significantly shorter overall survival (OS) than the stage- and subtype-matched FBC patients11,12. Somatic genetic alterations typically occurring in ER-positive, human epidermal growth factor receptor 2 (HER2)-negative FBC are less common in MBC, such as TP53 and PIK3CA mutations.
and 16q loss. Therefore, understanding the tumour biology and underlying mechanisms of sex-specific differences may contribute to optimizing the management of MBC.

Multigene profiling assays, such as Oncotype Dx, MammaPrint and EndoPredict, have been developed for prognostic assessment of breast cancer based on European and American populations. Whether these multigene tests are appropriate to Asian populations needs further validation. RecurIndex is a multigene prognostic test developed based on Chinese genes and clinicopathological features such as age, lymphovascular invasion (LVI), ER and lymph node status. With 44 scores as the threshold value, the accuracy of RecurIndex for predicting local–regional recurrence (LRR) in FBC can be up to 93%. Regardless of cancer subtypes or nodal status, RecurIndex can independently predict the risk of LRR in FBC. Additionally, it is also demonstrated to predict the risk of distant recurrence (DR). In a recent study, 2 clinical-genomic models (recurrence index for local recurrence, RI-LR; recurrence index for distant recurrence, RI-DR) derived from RecurIndex test have been established, among which RI-DR is found more appropriate to Chinese FBC than Oncotype Dx in the prediction of DR. To date, there are no studies reporting the application of RecurIndex in MBC. In this study, we first attempted to investigate the role of RecurIndex in predicting the prognosis of Chinese MBC patients.

| Characteristics                          | Description          |
|------------------------------------------|----------------------|
| Age, years, (x±s)                        | 63.8 ± 12.5          |
| Lymphovascular invasion                  |                      |
| Absent/focal                             | 30 (69.8)            |
| Prominent                                | 13 (30.2)            |
| Tumor grade                              |                      |
| I–II                                     | 37 (86.0)            |
| III                                      | 6 (14.0)             |
| Tumor T stage                            |                      |
| T1                                       | 19 (44.2)            |
| T2                                       | 23 (53.5)            |
| T3                                       | 1 (2.3)              |
| Tumor N stage                            |                      |
| N0                                       | 23 (53.5)            |
| N1                                       | 12 (27.9)            |
| N2                                       | 6 (14.0)             |
| N3                                       | 2 (4.7)              |
| Ki-67 expression                         |                      |
| < 15%                                    | 5 (11.6)             |
| 15–30%                                   | 23 (53.5)            |
| > 30%                                    | 15 (34.9)            |
| Estrogen receptor/progesterone receptor status |        |
| Positive                                 | 42 (97.7)            |
| Negative                                 | 1 (2.3)              |
| Human epidermal growth factor receptor 2 status |   |
| Positive                                 | 5 (11.6)             |
| Negative                                 | 38 (88.4)            |
| Adjuvant endocrine therapy               |                      |
| Yes                                      | 29 (67.4)            |
| No                                       | 14 (32.6)            |
| Adjuvant chemotherapy                    |                      |
| Yes                                      | 21 (48.8)            |
| No                                       | 22 (51.2)            |
| Adjuvant radiotherapy                    |                      |
| Yes                                      | 13 (30.2)            |
| No                                       | 30 (69.8)            |
| Recurrence index for local recurrence    |                      |
| Low-risk                                 | 26 (60.5)            |
| High-risk                                | 17 (39.5)            |
| Recurrence index for distant recurrence  |                      |
| Low-risk                                 | 17 (39.5)            |
| High-risk                                | 26 (60.5)            |

Table 1. Clinicopathological features of included patients, n (%).
Results
Clinicopathological features of included patients. Between 2009 and 2018, there were a total of 54 consecutive MBC patients who underwent surgeries in The Fourth Hospital of Hebei Medical University. After 5 cases of loss to follow-up and 6 unqualified tumour samples were excluded, 43 patients were finally enrolled into the study, with the median follow-up duration of 36 months. The clinicopathological features of patients are listed in Table 1. As it shown, the patients were at the age of (63.8 ± 12.5) years, 86.0% (37/43) were likely to have tumour grade of I-II, 97.7% (42/43) were ER/progesterone receptor (ER/PR)-positive and 88.4% (38/43) were HER2-negative. Only 30.2% of patients (13/43) had prominent LVI. Of these patients, the proportions of patients receiving adjuvant endocrine therapy, adjuvant chemotherapy and adjuvant radiotherapy were 67.4% (29/43), 48.8% (21/43) and 30.2% (13/43), respectively. According to the assessment of RI-LR, there were 26 (60.5%) low-risk and 17 (39.5%) high-risk patients, while based on RI-DR there were 17 (39.5%) low-risk and 26 (60.5%) high-risk patients.

Association of RI-LR and RI-DR with clinicopathological features. The clinicopathological features of low- and high-risk patients stratified by RI-LR and RI-DR were compared in Tables 2 and 3, respectively. For RI-LR, tumour N stage showed statistically significant between low- and high-risk patients (P < 0.001; Table 2). For RI-DR, significant differences were presented in tumour grade (P = 0.033), T stage (P = 0.043) and N stage (P < 0.001) between low- and high-risk patients (Table 2).

Association of RI-LR and RI-DR with clinical outcomes. For RI-LR, analysis of overall survival (OS) of low- and high-risk patients showed no statistically significant differences (P = 0.460; Fig. 1A). For RI-DR, however, high-risk patients had a significantly worse OS (69.2% vs. 100.0%, P = 0.044; Fig. 1B), distant recurrence-free survival (DRFS) (73.1% vs. 100.0%, P = 0.035; Fig. 1C), and progression-free survival (PFS) (65.4% vs. 100.0%, P = 0.019; Fig. 1D) than low-risk patients.

During the follow up, 17 (100.0%, 17/17) low-risk patients identified by RI-DR did not suffer from any recurrences or deaths, while 9 (34.6%, 9/26) high-risk patients were subjected to recurrences or deaths. According

### Table 2. Correlation between RI-LR and clinicopathological features, n (%).

| Characteristics                      | Low-risk group (N=17) | High-risk group (N=26) | P      |
|--------------------------------------|-----------------------|------------------------|--------|
| Age, years, (x±s)                    | 60.53 ± 13.87         | 65.88 ± 11.27          | 0.194  |
| Tumor grade                          |                       |                        | 0.055  |
| I-II                                 | 25 (96.2)             | 12 (70.6)              |        |
| III                                  | 1 (3.8)               | 5 (29.4)               |        |
| Ki-67 expression                     |                       |                        | 0.369  |
| <15%                                 | 16 (61.5)             | 7 (41.2)               |        |
| 15–30%                               | 7 (26.9)              | 8 (47.1)               |        |
| >30%                                 | 3 (11.5)              | 2 (11.8)               |        |
| Tumour T stage                       |                       |                        | 0.650  |
| T1                                   | 12 (46.2)             | 7 (41.2)               |        |
| T2                                   | 13 (50.0)             | 10 (58.8)              |        |
| T3                                   | 1 (3.8)               | 0 (0.0)                |        |
| Tumour N stage, n (%)                |                       |                        | <0.001 |
| N0                                   | 21 (80.8)             | 2 (11.8)               |        |
| N1                                   | 3 (11.5)              | 9 (52.9)               |        |
| N2                                   | 2 (7.7)               | 4 (23.5)               |        |
| N3                                   | 0 (0.0)               | 2 (11.8)               |        |
| LVI                                  |                       |                        | 0.356  |
| Absent/focal                         | 20 (76.9)             | 10 (58.8)              |        |
| Prominent                            | 6 (23.1)              | 7 (41.2)               |        |
| ER/PR status                         |                       |                        | 0.828  |
| Positive                             | 26 (100.0)            | 16 (94.1)              |        |
| Negative                             | 0 (0.0)               | 1 (5.9)                |        |
| HER2 status                          |                       |                        | 0.643  |
| Positive                             | 23 (88.5)             | 15 (88.2)              |        |
| Negative                             | 3 (11.5)              | 2 (11.8)               |        |
to the subtypes, 22 patients not receiving adjuvant chemotherapy were screened out. Despite no statistically significant difference, the low-risk patients without adjuvant chemotherapy seemed to have a longer OS than the high-risk patients without adjuvant chemotherapy ($P = 0.140$; Fig. 2). Among the patients without adjuvant chemotherapy, 12 cases were predicted at low risk of recurrence. The final follow-up showed that these 12 patients did not experience any recurrences or deaths. All these findings suggested that RI-DR was conductive to identifying the patients at low risk of recurrence for MBC, and these patients might be exempt from postoperative adjuvant chemotherapy.

**Discussion**

Genomic testing is thought to play an important role in aiding clinical decision-making and better balancing the efficacy and detriments of adjuvant therapies, which is valuable in avoiding overtreatments or harmful treatments$^{21,22}$. In this study, RecurIndex, a multigene prognostic test, was used to assess the risk of LRR and DR in MBC. The results showed no statically significant association of RI-LR with MBC prognosis. However, RI-DR could effectively predict the DRFS, PFS and OS of MBC patients and identify those at low risk of recurrence to make them exempt from adjuvant chemotherapy. These findings suggested that RI-DR could be a potential prognostic tool for MBC.

RI-DR, a clinical-genomic model generated by clinical variables and genetic information, has a relatively high sensitivity and a relatively high negative predictive value. It is useful in the identification of low-risk breast cancer patients, particularly in those with Asian genetic backgrounds$^{23}$. A previous study showed that RI-DR contributed to classifying Asian endocrine-responsive breast cancer patients with both negative and positive lymph nodes into the low- and high-risk groups based on 10-year DR$^{24}$. In another study performed by Huang et al., it was also found a significant difference in 10-year DR-free intervals between low- and high-risk groups classified by RI-DR$^{19}$. These studies all confirmed the utility of RI-DR in clinic.

Currently, National Comprehensive Cancer Network (NCCN) guidelines have proposed that multigene assays Oncotype Dx and MammaPrint can be used to evaluate the risk of recurrence in FBC according to certain cancer-gene expression patterns. In addition to providing information on recurrence prognosis, they also have predictive ability and can indicate who may benefit from additional chemotherapy$^{25}$. With a high concordance rate with Oncotype Dx, RecurIndex possesses potential for helping clinicians make more informed decisions on adjuvant chemotherapy in Asian FBC patients$^{26,27}$. Among the MBC patients without adjuvant chemotherapy in our study, the low-risk patients stratified by RI-DR tended to have better OS than the high-risk patients, and

| Characteristics | Low-risk group (N=17) | High-risk group (N=26) | $P$ |
|-----------------|-----------------------|------------------------|-----|
| Age, years, ($x \pm s$) | 64.45 ± 11.81 | 64.16 ± 13.20 | 0.942 |
| Tumor grade | | | 0.033 |
| I–II | 17 (100.0) | 20 (76.9) | |
| III | 0 (0.0) | 6 (23.1) | |
| Ki-67 expression | | | 0.140 |
| <15% | 2 (11.8) | 3 (11.5) | |
| 15–30% | 12 (70.6) | 11 (42.3) | |
| >30% | 3 (17.6) | 12 (46.2) | |
| Tumour T stage | | | 0.043 |
| T1 | 11 (64.7) | 7 (26.9) | |
| T2 | 6 (35.3) | 18 (69.2) | |
| T3 | 0 (0.0) | 1 (3.8) | |
| Tumour N stage, n (%) | | | 0.003 |
| N0 | 15 (88.2) | 8 (30.8) | |
| N1 | 1 (5.9) | 11 (42.3) | |
| N2 | 1 (5.9) | 5 (19.2) | |
| N3 | 0 (0.0) | 2 (7.7) | |
| LVI | | | 0.266 |
| Absent/focal | 14 (82.3) | 0 (0.0) | |
| Prominent | 3 (17.6) | 10 (38.5) | |
| ER/PR status | | | 1.000 |
| Positive | 17 (100.0) | 25 (96.2) | |
| Negative | 0 (0.0) | 1 (3.8) | |
| HER2 status | | | 0.643 |
| Positive | 1 (5.9) | 4 (15.4) | |
| Negative | 16 (94.1) | 22 (84.6) | |

Table 3. Correlation between RI-DR and clinicopathological features, n (%). LVI lymphovascular invasion, ER/PR estrogen receptor/progesterone receptor, HER2 human epidermal growth factor receptor 2, RI-DR recurrence index for distant recurrence.
did not experience any recurrences or deaths, suggesting that the low-risk patients identified by RI-DR might be exempt from postoperative adjuvant chemotherapy. In a study performed by Giordano et al., 135 out of 156 MBC patients were identified with distant metastases, among whom 32 cases received chemotherapy, including 84% with adjuvant chemotherapy, 6% with neoadjuvant chemotherapy, and 9% with both. The results showed that 10-year OS rates of patients with lymph node-negative disease and those with lymph node-positive disease were 75% and 43%, respectively, indicating that the death risk of MBC patients with lymph node-positive disease did not decrease significantly after adjuvant chemotherapy. There is another study showing that adjuvant chemotherapy may be skipped for stage I-IIA MBC patients. Additionally, our results also revealed that 4 high-risk patients identified by RI-DR who developed recurrence or deaths might benefit from adjuvant chemotherapy, suggesting that adjuvant chemotherapy may be taken into consideration in MBC patients at high risk of recurrence or metastasis. Hence, RI-DR can not only provide clinical outcome information before treatment, but also contributes to risk–benefit assessment of systemic adjuvant chemotherapy.

The major superiority of our study was that it first employed RecurIndex, a multigene prognostic test, to assess the prognosis of Chinese MBC patients and showed the clinical utility of RI-DR in MBC. Additionally, RI-DR can identify the patients at low risk of recurrence, probably leading to a reduction of adjuvant chemotherapy. It may be a necessary study whether MBC patients should receive postoperative adjuvant chemotherapy or not. However, there were also several limitations in our study. First, our study was a retrospective, single-center study with the small sample size, which may affect the statistical power and reliability of results. Second, we did not find statically significant association of RI-LR with MBC prognosis, which might be associated with the small sample size. In the future, more well-designed, large-scale studies should be implemented to further investigate the correlation between RI-LR and the prognosis in MBC.

Figure 1. Comparison on the survival curves of low- and high-risk patients stratified by RI-LR and RI-DR. (a) Overall survival of low- and high-risk patients identified by RI-LR; (b) Overall survival of low- and high-risk patients identified by RI-DR; (c) Distant recurrence-free survival of low- and high-risk patients identified by RI-DR; (d) Progression-free survival of low- and high-risk patients identified by RI-DR.
Conclusions
RI-DR can better predict the DRFS, PFS and OS of MBC patients and identify those at low risk of recurrence to make them exempt from adjuvant chemotherapy to the greatest extent, which may serve as a potential prognostic tool for MBC. However, the association of RI-LR with clinical outcomes in MBC still needs large-scale studies to further investigate.

Methods
Patients and data description. In this study, the clinicopathological data of 43 consecutive MBC patients undergoing surgeries in The Fourth Hospital of Hebei Medical University between 2009 and 2018 were analysed retrospectively. Their formalin-fixed and paraffin-embedded (FFPE) tumour samples were detected using RecurIndex test. Written consent forms were obtained from all the patients. The study was approved by the Institutional Review Board of The Fourth Hospital of Hebei Medical University (Approval No.: 20211372), and all the procedures performed were in accordance with relevant guidelines/regulations, as well as the 1964 Helsinki declaration and its later amendments.

The clinicopathological data of patients were collected by reviewing the electronic medical record, including age, LVI, tumour grade, tumour stage, Ki-67 expression, ER/PR and HER2 status, as well as presence or absence of adjuvant endocrine therapy, adjuvant chemotherapy and adjuvant radiotherapy.

RecurIndex test. As an in vitro test, RecurIndex utilized real-time fluorescent quantitative nucleic-acid amplification technology to detect the ribonucleic acids (RNA) extracted from FFPE breast cancer samples, which was used for analysing gene-expression profiling of breast cancer. The primer pairs of genes included in RecurIndex test were complementary to the messenger RNA sequence of each target gene, and PanelStation was used for real-time fluorescent quantitative amplification. Based on gene-expression profiling of breast cancer and clinical factors, the risk scores of LRR and DR were calculated using analysis software.

A previous study has demonstrated that the best cut-off values of RecurIndex test for predicting LRR and DR are 8% and 4%, respectively. According to the RI-LR and RI-DR generated from RecurIndex test, patients were separately divided into the low- and high-risk groups. Postoperatively, all the patients were followed up by further consultations and telephones. The follow-up deadline was February, 2020.

Statistical analysis. The data in this study were managed using R software (version 4.0.1, The R Foundation). Normally distributed measurement data were expressed as mean ± standard deviation (x ± s), t-test was used. Non-normal distribution data were presented as the median and interquartile [M (Q1, Q3)], the Mann–Whitney U rank sum test was performed. The ranked data were presented as number of cases and percentiles n (%), χ² test or Fisher’s exact test was performed. The survival curves were drawn using Kaplan–Meier method and compared by Log-rank test. P<0.05 was considered statistically significant.

Ethics approval and consent to participate. The study was approved by the Institutional Review Board of The Fourth Hospital of Hebei Medical University (Approval No.: 20211372). All the patients included in this study had given informed consent, and all the procedures performed were in accordance with relevant guidelines/regulations, as well as the 1964 Helsinki declaration and its later amendments.
Data availability

The datasets used and/or analysed during the current study are available from the corresponding author on reasonable request.

Received: 30 November 2020; Accepted: 24 March 2021
Published online: 07 April 2021

References

1. Gucalp, A. et al. Male breast cancer: A disease distinct from female breast cancer. Breast Cancer Res. Treat. 173, 37–48. https://doi.org/10.1007/s10549-018-4921-9 (2019).
2. Korde, L. A. et al. Multidisciplinary meeting on male breast cancer: Summary and research recommendations. J. Clin. Oncol. 28, 2114–2122. https://doi.org/10.1200/JCO.2009.25.5729 (2010).
3. Abdelwahab Yousef, A. J. Male breast cancer: Epidemiology and risk factors. Semin. Oncol. 44, 267–272. https://doi.org/10.1053/j.seminoncol.2017.11.002 (2017).
4. Giordano, S. H., Cohen, D. S., Buzdar, A. U., Perkins, G. & Hortobagyi, G. N. Breast carcinoma in men: A population-based study. Cancer 101, 51–57. https://doi.org/10.1002/cncr.20312 (2004).
5. Darkeh, M. H. S. E. & Azavedo, E. Male breast cancer clinical features, risk factors, and current diagnostic and therapeutic approaches. Int. J. Clin. Med. 15, 1068–1086. https://doi.org/10.4236/ijicm.2014.517138 (2014).
6. Chen, W. et al. Hormone receptor-positive breast cancer has a worse prognosis in male than in female patients. Clin. Breast Cancer. 17, 356–366. https://doi.org/10.1016/j.cbc.2017.03.065 (2017).
7. Anderson, W. F., Althuis, M. D., Brinton, L. A. & Devesa, S. S. Is male breast cancer similar or different than female breast cancer?. Breast Cancer Res. Treat. 83, 77–86. https://doi.org/10.1007/BF03329414 (2004).
8. Cardoso, F. et al. Characterization of male breast cancer: Results of the EORTC 10855/TBCRC/BIG/NABCG International Male Breast Cancer Program. Ann. Oncol. 29, 405–417. https://doi.org/10.1093/annonc/mdx631 (2018).
9. Pritzlaff, M. et al. Male breast cancer in a multi-gene panel testing cohort: Insights and unexpected results. Breast Cancer Res. Treat. 161, 575–586. https://doi.org/10.1007/s10549-016-4085-4 (2017).
10. Evans, D. B. & Cricliholw, R. W. Carcinoma of the male breast and Klinefelter's syndrome: Is there an association?. CA Cancer J. Clin. 37, 246–251. https://doi.org/10.3322/caac.37.4.246 (1987).
11. Li, X. et al. A new clinical-genomic model to predict 10-year recurrence risk in primary operable breast cancer patients. Breast Cancer 23, 12–18. https://doi.org/10.1016/j.saco.2017.03.002 (2017).
12. Gref, J. M., Perzzi, C. M., Klimberg, V. S., Bailey, L. & Zurak, M. Gender differences in breast cancer: Analysis of 13,000 breast cancers in men from the National Cancer Data Base. Ann. Surg. Oncol. 19, 3199–3204. https://doi.org/10.1245/s10434-012-2479-2 (2012).
13. Piscuoglio, S. et al. The genomic landscape of male breast cancers. Clin. Cancer Res. 22, 4045–4056. https://doi.org/10.1158/1078-0432.CCR-15-2840 (2016).
14. Vermeulen, M. A. et al. Pathological characterisation of male breast cancer results of the EORTC 10855/TBCRC/BIG/NABCG International Male Breast Cancer Program. Eur. J. Cancer. 82, 219–227. https://doi.org/10.1016/j.ejca.2017.01.034 (2017).
15. Naoi, Y. & Noguchi, S. Multi-gene classifiers for prediction of recurrence in breast cancer patients. Breast Cancer 23, 121–128. https://doi.org/10.1007/s12282-015-0596-9 (2016).
16. Harris, L. N. et al. Use of biomarkers to guide decisions on adjuvant systemic therapy for women with early-stage invasive breast cancer: American Society of Clinical Oncology clinical practice guideline. J. Clin. Oncol. 34, 1134–1150. https://doi.org/10.1200/JCO.2015.65.2289 (2016).
17. Cheng, S. H. et al. An eighteen-gene classifier predicts locoregional recurrence in post-mastectomy breast cancer patients. EBioMedicine 5, 74–81. https://doi.org/10.1016/j.ebiom.2016.02.022 (2016).
18. Cheng, S. H. et al. Validation of the 18-gene classifier as a prognostic biomarker of distant metastasis in breast cancer. PLoS ONE 12, e0184372. https://doi.org/10.1371/journal.pone.0184372 (2017).
19. Huang, T. T., Chen, A. C., Lu, T. P., Lei, L. & Cheng, S. H. Clinical-genomic models of node-positive breast cancer: Training, testing, and validation. Int. J. Radiat. Oncol. Biol. Phys. 105, 637–648. https://doi.org/10.1016/j.ijrobp.2019.06.2546 (2019).
20. Huang, T. T. et al. A new clinical-genomic model to predict 10-year recurrence risk in primary operable breast cancer patients. Sci. Rep. 10, 8461. https://doi.org/10.1038/s41598-020-61535-9 (2020).
21. Cheng, M. C. et al. Clinical utility of multigene profiling assays in early-stage breast cancer. Curr. Oncol. 24, e403–e422. https://doi.org/10.3747/coc.24.3595 (2017).
22. Hannoun, M. B. et al. Cost-effectiveness analysis of multigene expression profiling assays to guide adjuvant therapy decisions in women with invasive early-stage breast cancer. Pharmacoeconomics 39, 27–46. https://doi.org/10.1007/s41397-019-00889-x (2020).
23. Yang, P. S. et al. A preliminary report of head-to-head comparison of 18-gene-based clinical-genomic model and oncotype DX 21-gene assay for predicting recurrence of early-stage breast cancer. Jpn. J. Clin. Oncol. 49, 1029–1036. https://doi.org/10.1093/jjco/hyz102 (2019).
24. Lei, L., Wang, X. J., Mo, Y. Y., Cheng, S. H. & Zhou, Y. DGM-CM6: A new model to predict distant recurrence risk in operable endocrine-responsive breast cancer. Front. Oncol. 10, 783. https://doi.org/10.3389/fonc.2020.00783 (2020).
25. Schunkert, E. M., Zhao, W. & Zanker, K. Breast cancer recurrence risk assessment: Is non-invasive monitoring an option?. Biomed. Hub 3, 1–17. https://doi.org/10.1515/biomedhub-2018-0029 (2018).
26. Huang, T. T., Pennarun, N., Cheng, Y. H., Horng, C. F., Lei, J., Cheng, H. C. Gene expression profiling in prognosis of distant recurrence in HR-positive and HER2-negative breast cancer patients. Oncotarget. 9, 23173–23182. https://doi.org/10.18632/oncotarget.25258 (2018).
27. Giordano, S. H. et al. Adjuvant systemic therapy for male breast carcinoma. Cancer 104, 2359–2364. https://doi.org/10.1002/cncr.21526 (2005).
28. Li, W. P. et al. The role of adjuvant chemotherapy in stage I-III male breast cancer: A SEER-based analysis. Ther. Adv. Med. Oncol. 12, 17588359209588358. https://doi.org/10.1177/1758835920958358 (2020).
29. Yu, X. F. et al. The effect of adjuvant chemotherapy in male breast cancer: 134 cases from a retrospective study. ESMO Open. 2, e000134. https://doi.org/10.1136/esmoopen-2016-000134 (2017).

Author contributions

S.Z., B.C.L., C.S. and Y.J.L. were responsible for the study design. M.L.Z., X.H.D., and N.W. performed statistical analysis. F.R.D. and J.Y.T. participated in interpretation of data. J.T.W, J.Z.L., W.L., C.Y., Y.P.L. and S.Y.N. collected the clinicopathological data. S.Z. and B.C.L. wrote the manuscript. C.S. and Y.J.L. was responsible for reviewing the manuscript. All the authors read and approved the final manuscript.
Competing interests
The authors declare no competing interests.

Additional information
Correspondence and requests for materials should be addressed to C.S. or Y.L.
Reprints and permissions information is available at www.nature.com/reprints.
Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2021